Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

Sarepta Therapeutics (SRPT) stock gains as Scotiabank upgrades it to Sector Outperform ting a compelling risk-reward setup. Read more here.

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the July 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

Sarepta Therapeutics (SRPT), maker of an Ebola vaccine, shares are climbing following news of the first patient contracting the disease in the U.S. Sarepta Therapeutics (SRPT), maker of an Ebola ...

Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector Perform to Sector Outperform. As of June 2, 2025, the average one-year ...